House of Lords written question – answered at on 7 November 2002.
asked Her Majesty's Government:
Further to the Written Answer by Lord Hunt of Kings Heath on 9 October (WA 26), why the National Health Service has not yet responded to the last appraisal by the National Institute for Clinical Excellence of therapies for patients with chronic hepatitis C;
What was the number of patients treated by the National Health Service for chronic hepatitis C in the United Kingdom in 2001; and how that number compared with Germany and France; and how the numbers of people identified as suffering from chronic hepatitis C in the three countries compare; and
What is the latest figure available for the number of patients treated for chronic hepatitis C in the United Kingdom during 2002.
Health authority allocations for 2002–03 were increased by £3,704 million, or 9.9 per cent. A key priority for the use of additional funding is the implementation of guidance from the National Institute for Clinical Excellence. From
The Department of Health does not collect information centrally on the number of patients receiving treatment for hepatitis C. Treatment for hepatitis C in Wales, Scotland and Northern Ireland is the responsibility of the devolved administrations.
It is estimated that the prevalence of hepatitis C antibody in the general population of the United Kingdom is about 0.5 per cent. Studies in France and Germany have estimated that the prevalence of hepatitis C antibody in the general population is around 1.0 per cent and 0.4 per cent respectively. About 80 per cent of those infected with hepatitis C develop chronic infection.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.